1
|
Xie Y, Shan M, Yu J, Du Y, Wu C, Liu S, Li J, Xiao Y, Yan Y, Li N, Qin J, Lan L, Wang Y. LINC00173 silence and estrone supply suppress ER + breast cancer by estrogen receptor α degradation and LITAF activation. Cancer Sci 2024; 115:2318-2332. [PMID: 38705575 PMCID: PMC11247560 DOI: 10.1111/cas.16201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2024] [Revised: 04/03/2024] [Accepted: 04/17/2024] [Indexed: 05/07/2024] Open
Abstract
Persistent activation of estrogen receptor alpha (ERα)-mediated estrogen signaling plays a pivotal role in driving the progression of estrogen receptor positive (ER+) breast cancer (BC). In the current study, LINC00173, a long non-coding RNA, was found to bind both ERα and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNFα) factor (LITAF), then cooperatively to inhibit ERα protein degradation by impeding the nuclear export of ERα. Concurrently, LITAF was found to attenuate TNFα transcription after binding to LINC00173, and this attenuating transcriptional effect was quite significant under lipopolysaccharide stimulation. Distinct functional disparities between estrogen subtypes emerge, with estradiol synergistically promoting ER+ BC cell growth with LINC00173, while estrone (E1) facilitated LITAF-transcriptional activation. In terms of therapeutic significance, silencing LINC00173 alongside moderate addition of E1 heightened TNFα and induced apoptosis, effectively inhibiting ER+ BC progression.
Collapse
Affiliation(s)
- Yu Xie
- School of Medicine, Nankai University, Tianjin, China
| | - Meihua Shan
- Department of Clinical Biochemistry, Army Medical University (Third Military Medical University), Chongqing, China
| | - Jing Yu
- School of Medicine, Nankai University, Tianjin, China
| | - Yongjun Du
- School of Medicine, Nankai University, Tianjin, China
| | - Chengkun Wu
- School of Medicine, Nankai University, Tianjin, China
| | - Shujing Liu
- School of Medicine, Nankai University, Tianjin, China
| | - Jiayin Li
- School of Medicine, Nankai University, Tianjin, China
| | - Yupeng Xiao
- School of Medicine, Nankai University, Tianjin, China
| | - Yan Yan
- Tianjin Key Laboratory of Oral and Maxillofacial Function Reconstruction, Hospital of Stomatology, Nankai University, Tianjin, China
| | - Ning Li
- Institute of Disaster and Emergency Medicine, Tianjin University, Tianjin, China
| | - Junfang Qin
- School of Medicine, Nankai University, Tianjin, China
| | - Lan Lan
- Department of Integrated Traditional & Western Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
| | - Yue Wang
- School of Medicine, Nankai University, Tianjin, China
- Tianjin Key Laboratory of Oral and Maxillofacial Function Reconstruction, Hospital of Stomatology, Nankai University, Tianjin, China
| |
Collapse
|
2
|
Rao L, Guo D, Wu JP. Cisplatin-resistance induces lung squamous carcinoma cell growth by nicotine-mediated α7nAchR/HDAC1/Cyclin D1/pRb cell cycle activation. Cell Biochem Funct 2024; 42:e3990. [PMID: 38504444 DOI: 10.1002/cbf.3990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2023] [Revised: 03/10/2024] [Accepted: 03/11/2024] [Indexed: 03/21/2024]
Abstract
The majority of adenocarcinoma lung cancer is found in nonsmokers. A history of tobacco use is more common in squamous cell carcinoma of the lung. The aim of this study is to identify the cisplatin (CDDP)-resistance that promotes lung squamous carcinoma cell growth through nicotine-mediated HDAC1/7nAchR/E2F/pRb cell cycle activation. Squamous cell carcinoma (NCI-H520 and NCI-H157) cells were examined after cisplatin and nicotine treatment by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay, cell migration assay, immunofluorescence staining, western blot analysis, and immunoprecipitation analysis. Consequently, CDDP is released from DNA and Rb phosphorylated pRb as a result of nicotine-induced cancer cell proliferation through 7nAchR, which then triggers the opening of the HDAC1 cell cycle. The cell cycle is stopped when CDDP adducts are present. Nicotine exerts cancer cytoprotective effects by allowing HDAC1 repair mechanisms to re-establish E2F promoting DNA stimulation cell cycle integrity in the cytosol and preventing potential CDDP and HDAC1 suppressed in the nuclear. Concentration expression of nicotine causes squamous carcinoma cell carcinogens to emerge from inflammation. COX2, NF-KB, and NOS2 increase as a result of nicotine-induced squamous carcinoma cell inflammation. Nicotine enhanced the cell growth-related proteins such as α7nAchR, EGFR, HDAC1, Cyclin D, Cyclin E, E2F, Rb, and pRb by western blot analysis. It also induced cancer cell inflammation and growth. As a result, we suggest that nicotine will increase the therapeutic resistance effects of CDDP. This has the potential to interact with nicotine through α7nAchR receptors and HDAC1/Cyclin D/E2F/pRb potentially resulting in CDDP therapy resistance, as well as cell cycle-induced cancer cell growth.
Collapse
Affiliation(s)
- Leh Rao
- Department of Medical Technology, Shaoguan University, Shaoguan City, Guangdong Province, People's Republic of China
- Department of Biomedicine, Chengdu Medical College, Chengdu, People's Republic of China
| | - Dan Guo
- Department of Medical Technology, Shaoguan University, Shaoguan City, Guangdong Province, People's Republic of China
| | - Jia-Ping Wu
- Department of Medical Technology, Shaoguan University, Shaoguan City, Guangdong Province, People's Republic of China
| |
Collapse
|
3
|
Saleh RO, Al-Ouqaili MTS, Ali E, Alhajlah S, Kareem AH, Shakir MN, Alasheqi MQ, Mustafa YF, Alawadi A, Alsaalamy A. lncRNA-microRNA axis in cancer drug resistance: particular focus on signaling pathways. Med Oncol 2024; 41:52. [PMID: 38195957 DOI: 10.1007/s12032-023-02263-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Accepted: 11/20/2023] [Indexed: 01/11/2024]
Abstract
Cancer drug resistance remains a formidable challenge in modern oncology, necessitating innovative therapeutic strategies. The convergence of intricate regulatory networks involving long non-coding RNAs, microRNAs, and pivotal signaling pathways has emerged as a crucial determinant of drug resistance. This review underscores the multifaceted roles of lncRNAs and miRNAs in orchestrating gene expression and cellular processes, mainly focusing on their interactions with specific signaling pathways. Dysregulation of these networks leads to the acquisition of drug resistance, dampening the efficacy of conventional treatments. The review highlights the potential therapeutic avenues unlocked by targeting these non-coding RNAs. Developing specific inhibitors or mimics for lncRNAs and miRNAs, alone or in combination with conventional chemotherapy, emerges as a promising strategy. In addition, epigenetic modulators, immunotherapies, and personalized medicine present exciting prospects in tackling drug resistance. While substantial progress has been made, challenges, including target validation and safety assessment, remain. The review emphasizes the need for continued research to overcome these hurdles and underscores the transformative potential of lncRNA-miRNA interplay in revolutionizing cancer therapy.
Collapse
Affiliation(s)
- Raed Obaid Saleh
- Department of Medical Laboratory Techniques, Al-Maarif University College, Al-Anbar, Iraq.
| | - Mushtak T S Al-Ouqaili
- Department of Microbiology, College of Medicine, University of Anbar, Ramadi, Anbar, Iraq
| | - Eyhab Ali
- College of Chemistry, Al-Zahraa University for Women, Karbala, Iraq
| | - Sharif Alhajlah
- Department of Medical Laboratories, College of Applied Medical Sciences, Shaqra University, 11961, Shaqra, Saudi Arabia.
| | | | - Maha Noori Shakir
- Department of Medical Laboratories Technology, AL-Nisour University College, Baghdad, Iraq
| | | | - Yasser Fakri Mustafa
- Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, 41001, Iraq
| | - Ahmed Alawadi
- College of Technical Engineering, The Islamic University, Najaf, Iraq
- College of Technical Engineering, The Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq
- College of Technical Engineering, The Islamic University of Babylon, Babylon, Iraq
| | - Ali Alsaalamy
- College of Technical Engineering, Imam Ja'afar Al-Sadiq University, Al-Muthanna, 66002, Iraq
| |
Collapse
|
4
|
Suzuki T, Sakai S, Ota K, Yoshida M, Uchida C, Niida H, Suda T, Kitagawa M, Ohhata T. Expression of Tumor Suppressor FHIT Is Regulated by the LINC00173-SNAIL Axis in Human Lung Adenocarcinoma. Int J Mol Sci 2023; 24:17011. [PMID: 38069335 PMCID: PMC10707390 DOI: 10.3390/ijms242317011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Revised: 11/27/2023] [Accepted: 11/28/2023] [Indexed: 12/18/2023] Open
Abstract
Long non-coding RNAs (lncRNAs) play a critical role in a variety of human diseases such as cancer. Here, to elucidate a novel function of a lncRNA called LINC00173, we investigated its binding partner, target gene, and its regulatory mechanism in lung adenocarcinoma, including the A549 cell line and patients. In the A549 cell line, RNA immunoprecipitation (RIP) assays revealed that LINC00173 efficiently binds to SNAIL. RNA-seq and RT-qPCR analyses revealed that the expression of FHIT was decreased upon LINC00173 depletion, indicating that FHIT is a target gene of LINC00173. Overexpression of SNAIL suppressed and depletion of SNAIL increased the expression of FHIT, indicating that SNAIL negatively regulates FHIT. The downregulation of FHIT expression upon LINC00173 depletion was restored by additional SNAIL depletion, revealing a LINC00173-SNAIL-FHIT axis for FHIT regulation. Data from 501 patients with lung adenocarcinoma also support the existence of a LINC00173-SNAIL-FHIT axis, as FHIT expression correlated positively with LINC00173 (p = 1.75 × 10-6) and negatively with SNAIL (p = 7.00 × 10-5). Taken together, we propose that LINC00173 positively regulates FHIT gene expression by binding to SNAIL and inhibiting its function in human lung adenocarcinoma. Thus, this study sheds light on the LINC00173-SNAIL-FHIT axis, which may be a key mechanism for carcinogenesis and progression in human lung adenocarcinoma.
Collapse
Grants
- 19H03501 Ministry of Education, Culture, Sports, Science and Technology of Japan
- 22H02901 Ministry of Education, Culture, Sports, Science and Technology of Japan
- 20K07569 Ministry of Education, Culture, Sports, Science and Technology of Japan
- NA Project Mirai Cancer Research Grants, the Princes Takamatsu Cancer Research Foundation
- NA The Smoking Research Foundation
- NA Hamamatsu University School of Medicine Grant-in-Aid
Collapse
Affiliation(s)
- Takahito Suzuki
- Department of Molecular Biology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
| | - Satoshi Sakai
- Department of Molecular Biology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
| | - Kosuke Ota
- Department of Molecular Biology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
| | - Mika Yoshida
- Department of Molecular Biology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
| | - Chiharu Uchida
- Advanced Research Facilities & Services, Preeminent Medical Photonics Education & Research Center, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
| | - Hiroyuki Niida
- Department of Molecular Biology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
| | - Takafumi Suda
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
| | - Masatoshi Kitagawa
- Department of Molecular Biology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
| | - Tatsuya Ohhata
- Department of Molecular Biology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
| |
Collapse
|
5
|
Zhou C, Huang Y, Tian Y, Zhang B, Yang X. LncRNA Linc00173 may be a potential prognostic biomarker in human solid tumors: a meta-analysis and bioinformatics analysis. Mol Cell Biochem 2023; 478:2553-2565. [PMID: 36894691 DOI: 10.1007/s11010-023-04684-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2023] [Accepted: 02/19/2023] [Indexed: 03/11/2023]
Abstract
Despite advances in diagnostic techniques and treatments, cancer remains one of the leading causes of death worldwide.Therefore, finding new biomarkers and therapeutic targets is crucial for improving the diagnosis and treatment of human cancer.LncRNA Linc00173 is a newly identified tumor marker, and in this study, we aimed to explore the relationship between Linc00173 and clinicopathological features and patient prognosis. By using The Cochrane Library, EMbase, Web of Science, PubMed, OVID, we conducted a complete and thorough literature search from its inception to November 10, 2022.Meta-analysis was performed using Stata SE16.0 software. Nine studies involving 1102 patients were included.Meta-analysis showed that the overexpression of Linc00173 was significantly associated with poorer OS (HR = 1.76,95%CI:1.36-2.26, P < 0.001) and shorter DFS (HR = 1.89, 95%CI:1.49-2.40,P < 0.001),and was significantly associated with gender (male) (OR = 1.31,95% CI:1.01-1.69, P = 0.042), tumor size (large) (OR = 1.34,95% CI:1.01-1.78, P = 0.045), and lymph node metastasis (positive) (OR = 1.72,95% CI:1.03-2.88, P = 0.038). Overexpression of Linc00173 is associated with poor prognosis in cancer patients and is a potential prognostic biomarker and therapeutic target.
Collapse
Affiliation(s)
- Cong Zhou
- The First Clinical Medical College of Gansu University of Traditional Chinese Medicine, Lanzhou, 730000, Gansu, China
| | - Yalong Huang
- The First Clinical Medical College of Gansu University of Traditional Chinese Medicine, Lanzhou, 730000, Gansu, China
| | - Yong Tian
- School of Clinical Medicine, Ningxia Medical University, Yinchuan, 750000, China
| | - Bangxing Zhang
- School of Clinical Medicine, Ningxia Medical University, Yinchuan, 750000, China
| | - Xiaojun Yang
- Department II of General Surgery, Gansu Provincial Hospital, Lanzhou, 73000, China.
- The First Clinical Medical College of Lanzhou University, Lanzhou University, Lanzhou, 730000, China.
- Gansu Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology, Gansu Provincial Hospital, Lanzhou, 730000, China.
- Gansu Research Center of Prevention and Control Project for Digestive Oncology, Gansu Provincial Hospital, Lanzhou, 730000, China.
| |
Collapse
|